SHANGHAI GROWTH(00770)发布公告，于2026年1月31日，公司未经审核的每股资产净值为0.04美 元。 ...

Core Viewpoint - Shenzhen Hongye Jiyuan Geotechnical Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange for the second time, with Guangyin International as its sole sponsor [1] Group 1: Company Overview - Hongye is the largest non-state-owned geotechnical engineering company in South China by revenue projected for 2024 [1] - The company ranks first among non-state-owned enterprises participating in large geotechnical engineering projects in South China, with a market share of 1.9% for 2024 [1] - Hongye is positioned as the second-largest non-state-owned enterprise in China's top 10 foundation construction companies for 2024 [1] Group 2: Service Offerings - The company has over 23 years of experience in geotechnical engineering since its establishment in 2002 [3] - Hongye primarily focuses on providing geotechnical engineering services, including: - Pile foundation engineering - Excavation engineering - Combined pile foundation and excavation support engineering [3]

Core Viewpoint - China National Pharmaceutical Group's innovative drug Bemosituzumab (brand name: Andevate) has received approval from the National Medical Products Administration (NMPA) for a new indication in treating unresectable stage III non-small cell lung cancer (NSCLC) patients who have not progressed after platinum-based chemotherapy [1] Group 1 - The approval is based on positive results from the R-ALPS study, which was presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting [1] - The study included patients with locally advanced or unresectable stage III NSCLC who had not progressed after synchronous/sequential chemoradiotherapy, comparing Bemosituzumab to a placebo [1] Group 2 - The median follow-up time was 19.4 months, with a median progression-free survival (PFS) of 9.69 months for the Bemosituzumab group compared to 4.17 months for the placebo group (HR=0.53, 95% CI 0.39-0.72, p<0.0001), indicating a 47% reduction in the risk of disease progression or death [2] - Subgroup analyses showed consistent benefit trends across various groups, demonstrating the broad applicability of this treatment [2] - Overall survival (OS) data is not yet mature, with median OS not reached, but a trend towards OS benefit was observed (HR=0.76, 95% CI 0.50-1.14) [2] Group 3 - The incidence of grade 3 or higher treatment-related adverse events (TRAEs) was 29.4% in the Bemosituzumab group compared to 19.7% in the placebo group [2] - Bemosituzumab is the third PD-L1 inhibitor approved in China for consolidation therapy after radical chemoradiotherapy for locally advanced or unresectable NSCLC [2] - The company aims to continue focusing on innovation in lung cancer treatment, developing a pipeline that covers multiple molecular subtypes and treatment scenarios to enhance patient survival benefits [2]

Core Viewpoint - Beihai Kangcheng-B (01228) has announced a subscription agreement to issue a total of 84.0336 million subscription shares at a price of HKD 2.38 per share, representing a discount of approximately 14.70% compared to the closing price of HKD 2.79 on February 13, 2026 [1] Group 1: Subscription Details - The total amount raised from the subscription is expected to be approximately HKD 200 million, with a net amount of about HKD 199 million after deducting related expenses [1] - The net issue price per subscription share is estimated to be HKD 2.37 [1] Group 2: Use of Proceeds - The net proceeds from the subscription will be used for working capital for commercialized products and maintenance of registrations, research and development expenses for existing product lines, and settlement of trade payables of the group [1]

根据本公司的章程细则，董事会可填补本公司核数师职位的任何临时空缺。继罗兵咸永道辞任后，董事 会经审核委员会建议，已决议委任国卫会计师事务所有限公司(国卫)为本公司新任核数师，以填补临时 空缺，自2026年2月14日起生效(该委任)。 瑞尔集团(06639)发布公告，罗兵咸永道会计师事务所(罗兵咸永道)已辞任本公司核数师，自2026年2月 13日起生效。 ...

据港交所2月15日披露，深圳市德兰明海新能源股份有限公司(简称：德兰明海)向港交所主板递交上市 申请书，清科资本为其独家保荐人。该公司以BLUETTI品牌经营，为领先的便携储能产品供应商和创 新者。根据弗若斯特沙利文的资料，该公司以收入占比(6.6%)及出货量占比(7.5%)计算在全球位居第 四，彰显在快速增长产业中的领导地位。 据招股书，自2020年推出BLUETTI品牌以来，该公司凭借快速产品迭代(由内部研发团队支持)及全通路 品牌建设实现迅速扩张，已建立显著的全球品牌影响力，产品销往超过120个国家与地区。截至2025年 12月31日，该公司在全球累计出货超过350万台储能产品。 ...

据港交所2月15日披露，上海哥瑞利软件股份有限公司(简称：哥瑞利)向港交所主板递交上市申请书， 国泰君安国际、民银资本为其联席保荐人。根据弗若斯特沙利文的资料，按智能制造软件解决方案产生 的收入计，于2024年，该公司在中国泛半导体智能制造软件市场的国内泛半导体智能制造软件解决方案 提供商中排名首位。 据招股书，该公司是泛半导体行业领先的智能制造软件解决方案提供商，专注于为泛半导体行业所应用 先进制造而量身定制的智能制造软件解决方案的研发与商业化。 ...

本公司一直积极与贷款人就解决有关落实重组主协议项下的安排的剩余事项进行商讨，并致力于为境外 债务落实整体重组方案。 伟能集团(01608)发布公告，截至本公告日期，本公司一直与贷款人合作解决有关达成重组主协议项下 的暂缓生效日期和重组生效日期的尚存事项;由于重组尚未生效，且最后截止日期未获达成协议延长， 重组主协议已根据其条款失效。本公司与贷款人已就最后截止日期届满进行磋商，寻求适当延长，以落 实重组主协议项下商定的安排。有关工作目前仍在进行中。 于2026年2月11日，本公司接获通知，法院已就针对本公司的呈请授出认可令;据此，尽管针对本公司的 呈请已被提出，倘本公司最终被颁令清盘，则自2025年11月28日起本公司已发行及缴足股份的所有转让 均不会根据《公司(清盘及杂项条文)条例》第182条被视为无效。 ...

陆控(06623)发布公告，赵容奭先生已通知董事会，其无意在雇佣合约于2026年3月31日届满后续约，并 将于雇佣合约于2026年3月31日届满时，不再担任本公司执行董事及首席执行官;谢永林先生辞任非执行 董事，自2026年2月17日起生效;付欣女士辞任非执行董事，自2026年2月17日起生效;蔡方方女士已获委 任为非执行董事，自2026年2月18日起生效;李佩锋先生已获委任为非执行董事，自2026年2月18日起生 效;及吉翔先生已获委任为本公司执行董事兼首席执行官，自2026年4月1日起生效。 ...

粤港湾控股(01396)发布公告，在摩根士丹利资本国际公司(MSCI)2026年2月指数审议结果中，本公司将 获纳入MSCI中国小型股指数(MSCI China Small Cap Index)成份股，于2026年2月27日收市后生效。 MSCI是全球知名的独立指数公司，覆盖全球资本市场。MSCI指数为全球投资经理广泛使用的投资基准 之一，MSCI指数成份股的变动可能对机构投资者调整或优化投资组合的决策具有一定影响力。 董事会相信，本公司获纳入MSCI中国小型股指数成份股代表资本市场对本集团的积极业务表现、投资 价值及发展潜力的进一步认可，预期将有利于提升本公司的公众知名度及增加本公司股份买卖的流动 性，从而进一步提升本公司的投资价值。 董事会谨此感谢股东及投资者的持续支持，本公司将进一步深化在AI业务领域的布局和发展，通过AI 硬件基础设施、AI算力资源整合与生态化服务的协同发力，服务于千行百业智能化升级。 ...